HONG KONG – Aware of the business potential of the biopharmaceutical market, including the growing prospects for biosimilars, Samsung Biologics Co. Ltd. is investing $2 billion into its biopharmaceutical arms.
HONG KONG – Powered by sales of biologics and other pharmaceutical products, Wuxi Pharmatech Inc. posted strong first quarter results hurt only by a depreciation in the Chinese RMB.
HONG KONG – Merck & Co. Inc. has signed a deal to sell nine of its ophthalmic products to Japan-based Santen Pharmaceutical Co. Ltd. The decision to spin off the products to its long-time partner is Merck's latest move out of the ophthalmic market.
HONG KONG – Four years after it was sidelined, a pentavalent vaccine produced by the Indian arm of Sanofi Pasteur (the vaccine division of Sanofi SA) – Shantha Biotechnics Ltd. – received prequalification status from the World Health Organization. The prequalification means that United Nations agencies like UNICEF can now purchase the vaccine for use across its programs, mostly in emerging countries.
HONG KONG – A Japanese research institute has closed a controversial chapter in its history by refusing to reinvestigate misconduct by a high-profile scientist and has set up a committee of outside experts to suggest future steps to prevent fraud.
HONG KONG – The U.S. FDA has, for the first time ever, approved the use of a biologic product made by a Chinese company in U.S. investigational new drug trials.
HONG KONG – A Japanese research institute has closed a controversial chapter in its history by refusing to reinvestigate misconduct by a high-profile scientist and has set up a committee of outside experts to suggest future steps to prevent fraud.
HONG KONG – Four years after it was sidelined, a pentavalent vaccine produced by the Indian arm of Sanofi Pasteur (the vaccine division of Sanofi SA) – Shantha Biotechnics Ltd. – received prequalification status from the World Health Organization. The prequalification means that United Nations agencies like UNICEF can now purchase the vaccine for use across its programs, mostly in emerging countries.
